Determination of liver fibrosis stages in Egyptian chronic hepatitis B patients by a noninvasive tool

Serag, Waleed M.; Mohamed, Mervat S.; Eysa, Basem; Abd-Elhamed, Sara Mahmoud

doi:10.3906/sag-1812-165

Cited by 1 publication

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The AUROC value of the APRI scores in this study was lower than the value, 0.80, that was found by Wai et al (18). In other studies on patients with chronic HBV, the AUROC values ranged from 0.639 to 0.878 (31)(32)(33). Although our results were consistent with the studies in the literature, the low AUROC value that we found may be associated with the low number of patients that were included in the study, as well as the patient group, which consisted of young patients without significant fibrosis.…”

Section: Discussioncontrasting

confidence: 78%

“…Our results were similar to the results of other studies in the literature. In the other studies, the AUROC value of FIB-4 was ranged from 0.646 to 0.812 for F≥2, and from 0.715 to 0.818 for F≥4 (31)(32)(33)(34). In our study, the FIB-4 score was more successful than the other non-invasive methods, APRI and ALBI, in terms of detecting the presence of significant fibrosis in patients with chronic HBV.…”

Section: Discussionsupporting

confidence: 44%

“…Therefore, it is a new model that uses serum albumin and bilirubin to assess the severity of liver function (35). It has a more significant performance compared to the Child-Pugh and MELD scores when predicting the long-term survival rate for patients with HBV-related cirrhosis (33). The number of studies that show a correlation between fibrosis and ALBI in patients with chronic HBV is quite low.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hepatit B Enfeksiyonunda Karaciğer Histopatolojik Evreleri ile Albumin-Bilirubin Skoru Arasındaki İlişki

Erdal¹,

BAKIR

Güney

et al. 2022

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Aim: In this study, sensitivity and specificity of the albumin-bilirubin (ALBI) score were investigated to detect significant liver fibrosis, and these findings were then compared to fibrosis-4 (FIB-4) and aspartate aminotransferase to platelet ratio index (APRI) scores. Material and Methods: A total of 69 patients were included in the study. Of these patients, 54 (78.3%) were male and 15 (21.7%) were female. Serology, molecular analysis, biochemical parameters, and pathology results of the patients who underwent a liver biopsy due to a chronic hepatitis B virus (HBV) infection, were retrospectively evaluated. ALBI, APRI, and FIB-4 scores were calculated. To predict the fibrosis stage, F≥2 and F≥4, ALBI, APRI, and FIB-4 scores were investigated using the receiver operator characteristic (ROC) curve analysis. Results: The area under the ROC curve with 95% confidence interval (CI) for the ALBI, APRI, and FIB-4 scores were 0.613 (95% CI: 0.463-0.762, p=0.160), 0.658 (95% CI: 0.513-0.803, p=0.040), and 0.731 (95% CI: 0.570-0.891, p=0.004), respectively, to predict the F≥2, and 0.758 (95% CI: 0.544-0.971, p=0.090), 0.604 (95% CI:0.451-0.757, p=0.490), and 0.923 (95% CI: 0.856-0.990, p=0.005), respectively, in prediction of F≥4. The sensitivity and specificity rates of the ALBI score were 61.1% and 64.7%, respectively, for the cut-off value of -2.81 in predicting F≥2, and 75.0% and 70.8% for the cut-off value of -2.78 in predicting F≥4. Conclusion: ALBI scores can be used to detect F≥2 in patients with chronic HBV. However, it is not yet clear whether this approach is superior to other non-invasive methods for detecting F≥4.

show abstract